Modification of Multidrug Resistance by Magnetic Exposure Indicated from the Point of View of Nuclear Medicine

从核医学的角度表明磁暴露对多药耐药性的改变

• 批准号: 09670954
• 负责人: NAKAMURA Kayoko
• 金额: $ 1.98万
• 依托单位: Keio University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 1997
• 资助国家: 日本
• 起止时间: 1997 至 1998
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-09670954/
• 关键词: Magnetic Exposure; Tumor; Chemosensitivity; Multidrug Resistance; Tc-99m-MIBI; P-glycoprotein; 抗がん剤; P-糖たん白質; P糖蛋白質

The effects of magnetic field on the chemosensitivity of tumor cells were investigated by using Tc-99m-MIBI uptake; which indicates the function of P-glycoprotein. The cells lines studies were anaplastic thyroid cancer cell lines established from patients; human epidermoid cell KB-31; KB-31 transfected with mdr gene KB-G2; and MRP-cell line CA-500. By the strong magnetic exposure for a short period (one hour) the Tc-99m-MIBI uptake in some tumor cells (not all cells) was reduced. Under weak magnetic field the Tc-99m-MIBI uptake was increased in all tumor cells studied. These effects were not altered in the presence of anti-P-glycoprotein antibody or verapamil that inhibits the function of P-glycoprotein. It can be, therefore, concluded that the magnetic effects were different from cell to cell, and that these effects were not specific for P-glycoprotein. Magnetic exposure may be one of modifications that reverse multidrug resistance of tumor cells. Tc-99m-MIBI uptake in cells is a good indicator to assess the multidrug resistance modification.

采用Tc-99 m-MIBI摄取法研究磁场对肿瘤细胞化疗敏感性的影响，表明P-糖蛋白的作用。细胞系研究是从患者中建立的间变性甲状腺癌细胞系;人表皮样细胞KB-31;用mdr基因KB-G2转染的KB-31;和MRP细胞系CA-500。通过短时间（1小时）的强磁暴露，某些肿瘤细胞（并非所有细胞）对Tc-99 m-MIBI的摄取减少。在弱磁场作用下，肿瘤细胞对~（99）Tc-MIBI的摄取均增加。这些作用在抗P-糖蛋白抗体或抑制P-糖蛋白功能的维拉帕米的存在下没有改变。因此，可以得出结论，磁效应在细胞与细胞之间是不同的，并且这些效应对于P-糖蛋白不是特异性的。磁暴露可能是逆转肿瘤细胞多药耐药的机制之一。细胞摄取Tc-99 m-MIBI是评价多药耐药修饰的良好指标。

项目成果

K. Nakamura et al.: "Assessment of MDR-reversing agents by Tc-99m-MIBI"Anticancer Research. 18-6C. 4921 (1998)

K. Nakamura 等人：“通过 Tc-99m-MIBI 评估 MDR 逆转剂”抗癌研究。

Nakamura K.et al,: "Assessment of MDR-reversing Agents by Tc-99m-MIBI" Anticancer Researcg. 18(6C). 4921 (1998)

Nakamura K.等人：“通过 Tc-99m-MIBI 评估 MDR 逆转剂”抗癌研究。

K.Nakamura et al.: "In vivo evaluation of P-glycoprotein by T-125-labelled MRK-16 monoclonal antibody or Tc-99m-MIBI"European Journal of Nuclear Medicine. 24(8). 869 (1997)

K.Nakamura 等人：“通过 T-125 标记的 MRK-16 单克隆抗体或 Tc-99m-MIBI 对 P-糖蛋白进行体内评估”欧洲核医学杂志。

K. Nakamura et al.: "In vivo evaluation of P-glycoprotein by I-125-labelled MRK-16 monoclonal antibody or Tc-99m-MIBI"European Journal of Nuclear Medicine. 24-8. 869 (1997)

K. Nakamura 等人：“通过 I-125 标记的 MRK-16 单克隆抗体或 Tc-99m-MIBI 对 P-糖蛋白进行体内评估”欧洲核医学杂志。

K.Nakamura,et al: "In vivo evaluation of P-glycoprotein by I-125-labelled MRK-16 monoclonal antibody or Tc-99m-MIBI" European Journal of Nuclear Medicine. 24(8). 869- (1997)

K.Nakamura 等人：“通过 I-125 标记的 MRK-16 单克隆抗体或 Tc-99m-MIBI 对 P-糖蛋白进行体内评估”《欧洲核医学杂志》。